These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

823 related items for PubMed ID: 18681215

  • 41. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.
    Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L.
    J Infect Dis; 2003 Jul 15; 188(2):179-93. PubMed ID: 12854072
    [Abstract] [Full Text] [Related]

  • 42. A safe, effective and affordable HIV vaccine--an urgent global need.
    Joseph J, Etcheverry F, Alcami J, María GJ.
    AIDS Rev; 2005 Jul 15; 7(3):131-8. PubMed ID: 16302460
    [Abstract] [Full Text] [Related]

  • 43. The immune response to HIV: implications for vaccine development.
    Bolognesi DP.
    Semin Immunol; 1993 Jun 15; 5(3):203-14. PubMed ID: 8347841
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development.
    Betts MR, Gray CM, Cox JH, Ferrari G.
    Expert Rev Vaccines; 2006 Aug 15; 5(4):505-16. PubMed ID: 16989631
    [Abstract] [Full Text] [Related]

  • 52. Funding support lacking in search for HIV vaccine.
    AIDS Alert; 1999 Jan 15; 14(1):5-7. PubMed ID: 11366091
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Hitting HIV where it hurts: an alternative approach to HIV vaccine design.
    Altfeld M, Allen TM.
    Trends Immunol; 2006 Nov 15; 27(11):504-10. PubMed ID: 16997629
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. South African village prepares for first HIV vaccine trial.
    Connett H.
    Nat Med; 2000 Nov 15; 6(11):1199-200. PubMed ID: 11062516
    [No Abstract] [Full Text] [Related]

  • 58. Transience of vaccine-induced HIV-1-specific CTL and definition of vaccine "response".
    Jamieson BD, Ibarrondo FJ, Wong JT, Hausner MA, Ng HL, Fuerst M, Price C, Shih R, Elliott J, Hultin PM, Hultin LE, Anton PA, Yang OO.
    Vaccine; 2006 Apr 24; 24(17):3426-31. PubMed ID: 16545508
    [Abstract] [Full Text] [Related]

  • 59. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand.
    Karnasuta C, Paris RM, Cox JH, Nitayaphan S, Pitisuttithum P, Thongcharoen P, Brown AE, Gurunathan S, Tartaglia J, Heyward WL, McNeil JG, Birx DL, de Souza MS, Thai AIDS Vaccine Evaluation Group, Thailand.
    Vaccine; 2005 Mar 31; 23(19):2522-9. PubMed ID: 15752839
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.